BRPI0811052A2 - Composições de proteção de isquemia/reperfusão e métodos de uso. - Google Patents

Composições de proteção de isquemia/reperfusão e métodos de uso.

Info

Publication number
BRPI0811052A2
BRPI0811052A2 BRPI0811052-2A2A BRPI0811052A BRPI0811052A2 BR PI0811052 A2 BRPI0811052 A2 BR PI0811052A2 BR PI0811052 A BRPI0811052 A BR PI0811052A BR PI0811052 A2 BRPI0811052 A2 BR PI0811052A2
Authority
BR
Brazil
Prior art keywords
ischemia
methods
protection compositions
reperfusion protection
reperfusion
Prior art date
Application number
BRPI0811052-2A2A
Other languages
English (en)
Inventor
Matthew T Andrews
Lester R Drewes
Greg Beilman
Original Assignee
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota filed Critical Univ Minnesota
Publication of BRPI0811052A2 publication Critical patent/BRPI0811052A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
BRPI0811052-2A2A 2007-04-12 2008-04-11 Composições de proteção de isquemia/reperfusão e métodos de uso. BRPI0811052A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91146007P 2007-04-12 2007-04-12
US2632108P 2008-02-05 2008-02-05
PCT/US2008/060100 WO2008128095A1 (en) 2007-04-12 2008-04-11 Ischemia/reperfusion protection compositions and methods of using

Publications (1)

Publication Number Publication Date
BRPI0811052A2 true BRPI0811052A2 (pt) 2015-01-27

Family

ID=42269849

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0811052-2A2A BRPI0811052A2 (pt) 2007-04-12 2008-04-11 Composições de proteção de isquemia/reperfusão e métodos de uso.

Country Status (12)

Country Link
US (4) US9186340B2 (pt)
EP (1) EP2146711A4 (pt)
JP (1) JP2010523714A (pt)
KR (1) KR20100016456A (pt)
CN (1) CN101677996A (pt)
AU (1) AU2008240211A1 (pt)
BR (1) BRPI0811052A2 (pt)
CA (1) CA2684213A1 (pt)
IL (1) IL201406A0 (pt)
MX (1) MX2009011002A (pt)
RU (1) RU2459624C2 (pt)
WO (1) WO2008128095A1 (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2146711A4 (en) 2007-04-12 2011-10-26 Univ Minnesota PROTECTIVE COMPOSITIONS AGAINST ISCHEMIA / REPERFUSION AND METHODS OF USE
SG10201502029RA (en) * 2010-04-08 2015-05-28 Hospital For Sick Children Use of remote ischemic conditioning for traumatic injury
NL2004569C2 (en) * 2010-04-16 2011-10-18 Angteq B V Compounds for prevention of cell injury.
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
RU2488388C1 (ru) 2012-05-24 2013-07-27 Ооо "Валента Интеллект" Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
ITMI20120913A1 (it) * 2012-05-28 2013-11-29 Nicoletta Maxia Uso della n-acetil-5-metossitriptamina o suoi analoghi per favorire il meccanismo di impianto dell' embrione, e relative composizioni e mezzi di coltura
UA107653U (uk) 2012-10-01 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів
WO2014153416A1 (en) 2013-03-19 2014-09-25 University Of South Florida Compositions and methods for producing elevated and sustained ketosis
CN104208059A (zh) * 2014-09-05 2014-12-17 中国医学科学院北京协和医院 褪黑素在制备保护吸烟引起血管损伤药物中的应用
US10596129B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10596131B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10736861B2 (en) 2016-03-11 2020-08-11 Axcess Global Sciences, Llc Mixed salt compositions for producing elevated and sustained ketosis
US10973792B2 (en) 2019-02-13 2021-04-13 Axcess Global Sciences, Llc Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
US10292952B2 (en) 2016-03-11 2019-05-21 Axcess Global Sciences, Llc Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US10973786B2 (en) 2016-03-11 2021-04-13 Axcess Global Sciences, Llc R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions
US10245243B1 (en) 2017-12-19 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10245242B1 (en) 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10596130B2 (en) 2017-12-19 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11185518B2 (en) 2017-12-19 2021-11-30 Axcess Global Sciences, Llc S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer
US20170266147A1 (en) * 2016-03-18 2017-09-21 Csilla Ari D'Agostino Methods of increasing latency of anesthetic induction using ketone supplementation
AU2017238103A1 (en) * 2016-03-21 2018-11-22 University Of South Florida Methods of improving motor function using ketone supplementation
AU2017322708A1 (en) * 2016-09-12 2019-03-21 University Of South Florida Neuroregeneration improved by ketone
US10307398B2 (en) 2016-09-20 2019-06-04 Regents Of The University Of Minnesota Resuscitation composition and methods of making and using
US9925164B1 (en) 2017-01-12 2018-03-27 Neuroenergy Ventures, Inc. Glyceryl 3-hydroxybutyrates for traumatic brain injury
EP3595628B1 (en) * 2017-03-16 2021-12-01 RepoCeuticals A/S Compositions for retarding the decomposition of melatonin in solution
EP3609484A4 (en) * 2017-04-12 2020-12-16 Cavaleri, Franco BUTYRATE AND BETA HYDROXYBUTYRATE COMPOSITIONS AND METHODS FOR THEIR USE
CN110891982B (zh) 2017-04-17 2023-12-22 芝加哥大学 向肠道递送短链脂肪酸以用于人体保健和疾病治疗的聚合物材料
US10179095B2 (en) * 2017-06-07 2019-01-15 Dr. Raymond Laboratories Autophage activating resveratrol topical composition for skin improvement and treatment
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US10512615B1 (en) 2018-08-27 2019-12-24 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US11241401B2 (en) 2020-02-06 2022-02-08 Axcess Global Sciences, Llc Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions
US11419836B2 (en) 2019-02-13 2022-08-23 Axcess Global Sciences, Llc Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
US10980772B2 (en) 2018-08-27 2021-04-20 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
US11129802B2 (en) 2018-08-27 2021-09-28 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
AU2018260927B1 (en) * 2018-05-25 2019-02-21 Graham Sherard Baldwin Methods and compositions for inhibiting a noxious insult
JP2020125254A (ja) * 2019-02-04 2020-08-20 株式会社協和 化粧料、紫外線に対する細胞保護剤、光老化防止剤
US20220288006A1 (en) 2019-05-30 2022-09-15 Neuroenergy Ventures, Inc. Glyceryl tris (beta-hydroxybutyrate) and neuronal transient ischemic attacks
US11033553B2 (en) 2019-06-21 2021-06-15 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US20230277484A1 (en) * 2022-03-04 2023-09-07 Guardian Biosciences, LLC Compositions and methods to promote brain health

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4298601A (en) * 1972-03-06 1981-11-03 Technutra, S.A. Method and formulations for the treatment of obesity
FR2490631A1 (fr) 1980-09-24 1982-03-26 Roussel Uclaf Nouvelle composition lipidique utilisable en dietetique, reanimation et therapeutique
US5141674A (en) * 1984-03-08 1992-08-25 Phares Pharmaceutical Research N.V. Methods of preparing pro-liposome dispersions and aerosols
US5100677A (en) * 1985-12-18 1992-03-31 Veech Richard L Fluid therapy with various organic anions
CA1264442A (en) * 1984-06-22 1990-01-16 Richard L. Veech Electrolyte solutions and in vivo use thereof
DE3581407D1 (de) * 1985-09-06 1991-02-21 Nestle Sa Bewahrung lebender gewebe.
US5719119A (en) * 1985-12-18 1998-02-17 British Technology Group, Ltd. Parenteral nutrition therapy with amino acids
US5049388A (en) * 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US5120763A (en) 1986-11-26 1992-06-09 Bar Ilan University Physiologically active and nutritional composition
WO1991002535A1 (en) 1989-08-11 1991-03-07 Basil, Inc. Cancer prevention composition and method
US5257985A (en) * 1989-12-04 1993-11-02 Richard Puhl Multi-chamber intravenous bag apparatus
US5098409A (en) * 1991-01-04 1992-03-24 Massachusetts Institute Of Technology Intravenous bag and monitoring method
US5654266A (en) * 1992-02-10 1997-08-05 Chen; Chung-Ho Composition for tissues to sustain viability and biological functions in surgery and storage
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5405333A (en) * 1992-12-28 1995-04-11 Richmond; Frank M. Liquid medicament bag with needleless connector fitting using boat assembly
US7083572B2 (en) * 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
US5814663A (en) * 1994-08-29 1998-09-29 Wisconsin Alumni Research Foundation Method for maintaining an existing level of body fat
JP4598203B2 (ja) 1995-12-01 2010-12-15 ビーティージー・インターナショナル・リミテッド 脳機能改善剤
US5700828A (en) * 1995-12-07 1997-12-23 Life Resuscitation Technologies, Inc. Treatment or prevention of anoxic or ischemic brain injury with melatonin-containing compositions
CN1315473C (zh) 1997-03-17 2007-05-16 英国技术集团国际有限公司 治疗组合物
US6323237B1 (en) * 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
US6316038B1 (en) * 1997-03-17 2001-11-13 Btg International Limited Therapeutic compositions
US6262111B1 (en) 1997-05-21 2001-07-17 Sloan-Kettering Institute For Cancer Research Method for increasing the concentration of ascorbic acid in brain tissues of a subject
US5853388A (en) * 1997-08-21 1998-12-29 Semel; David Intravenous bag with separate compartment
US6107349A (en) 1998-04-16 2000-08-22 Mantynen; Philip R. Method and composition for treating psoriasis
US6353015B1 (en) * 1998-08-26 2002-03-05 St. Elizabeth's Medical Center Method of treating neurodegenerative disorders
WO2000015216A1 (en) * 1998-09-15 2000-03-23 Btg International Limited Therapeutic compositions (ii)
US6232354B1 (en) * 1999-01-25 2001-05-15 Seng C. Tan Microcellular polymer foams and method for their production
DE60038100T2 (de) * 1999-02-26 2009-02-12 Johnson & Johnson Consumer Companies, Inc. Bioadhäsive antibakterielle wundheilungszusammensetzungen
US20010051652A1 (en) * 1999-04-28 2001-12-13 Ajinomoto Co., Inc. Method of treating paralysis of the extremities caused by cerebral infarction
US6890896B1 (en) * 1999-11-18 2005-05-10 Ceremedix, Inc. Compositions and methods for counteracting effects of reactive oxygen species and free radicals
US6579852B2 (en) * 2000-01-14 2003-06-17 Genset S.A. OBG3 globular head and uses thereof for decreasing body mass
US6391345B1 (en) * 2000-05-12 2002-05-21 Tim Heeg Cranberry seed oil, cranberry seed flour and a method for making
DE10028837A1 (de) * 2000-06-15 2001-12-20 Roche Diagnostics Gmbh Verfahren zum Nachweis von Influenza A/B-Viren
US20020077317A1 (en) 2000-12-15 2002-06-20 Das Undurti Narasimha Method of potentating the action of 2-methoxyoestradiol, statins and C-peptide of proinsulin
US20050129783A1 (en) * 2001-04-19 2005-06-16 Mccleary Edward L. Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health
AU2003297583B2 (en) 2002-11-26 2010-01-14 Biocon, Ltd Modified naturetic compounds, conjugates, and uses thereof
WO2004066995A1 (en) * 2003-01-31 2004-08-12 The University Of Hong Kong Method for treating ischemic stroke with melatonin
IL155666A (en) * 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
US6919483B2 (en) * 2003-05-23 2005-07-19 Mediquest Therapeutics, Inc. Immunomodulation with novel pharmaceutical compositions
WO2004108740A2 (en) 2003-06-03 2004-12-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives
GB0410266D0 (en) 2004-05-07 2004-06-09 Ketocytonyx Inc Treatment of apoptosis
GB0420856D0 (en) 2004-09-20 2004-10-20 Ketocytonyx Inc Cns modulators
US7947736B2 (en) 2004-07-16 2011-05-24 Btg International Limited Oligomeric compounds
US7485743B2 (en) 2004-07-20 2009-02-03 Btg International Limited Oligomeric ketone compounds
WO2006012490A2 (en) 2004-07-23 2006-02-02 Ketocytonyx Inc. Ketogenic saccharides
DK1796658T3 (en) 2004-09-21 2016-06-27 Btg Int Ltd dopaminergic mimetics
WO2006098767A2 (en) 2004-09-21 2006-09-21 Ketocytonyx Inc. Treatment of adhd
GB0427145D0 (en) * 2004-12-10 2005-01-12 Ketocytonyx Inc Compositions for use in surgery
EP2146711A4 (en) 2007-04-12 2011-10-26 Univ Minnesota PROTECTIVE COMPOSITIONS AGAINST ISCHEMIA / REPERFUSION AND METHODS OF USE

Also Published As

Publication number Publication date
US20110111049A1 (en) 2011-05-12
JP2010523714A (ja) 2010-07-15
US20140235690A1 (en) 2014-08-21
US20100197758A1 (en) 2010-08-05
US8728532B2 (en) 2014-05-20
CA2684213A1 (en) 2008-10-23
US9149450B2 (en) 2015-10-06
MX2009011002A (es) 2010-03-15
CN101677996A (zh) 2010-03-24
IL201406A0 (en) 2010-05-31
EP2146711A4 (en) 2011-10-26
WO2008128095A1 (en) 2008-10-23
US20160008325A1 (en) 2016-01-14
RU2009141713A (ru) 2011-05-20
KR20100016456A (ko) 2010-02-12
RU2459624C2 (ru) 2012-08-27
EP2146711A1 (en) 2010-01-27
AU2008240211A1 (en) 2008-10-23
US9186340B2 (en) 2015-11-17

Similar Documents

Publication Publication Date Title
BRPI0811052A2 (pt) Composições de proteção de isquemia/reperfusão e métodos de uso.
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
BRPI0913086A2 (pt) Composições antimicrobianas e métodos de uso
BRPI0912703A2 (pt) composições imuno-moduladoras e métodos para uso dessas
BRPI1012533A2 (pt) composto de piradazinona e uso do mesmo
BRPI0913424A2 (pt) composições agrícolas de baixa taxa de uso e métodos para o uso
BRPI0912717A2 (pt) Composição farmacêutica, e, uso de 5-azacitidina
BRPI0821668A2 (pt) Uso
BRPI0911688A2 (pt) "compostos de pirimidina, composições e métodos de uso"
BRPI0818003A2 (pt) inibidores de csf-1r, composições e métodos de uso
CR10847A (es) Compuesto heteromonociclico y uso del mismo
MX277069B (es) Composiciones colorantes
BRPI0907365A2 (pt) Composição antimicrobiana e uso
CR20130360A (es) Compuesto heterocíclico y su uso
BRPI0716327A2 (pt) Composto de fenilpropionamida e uso
BRPI0819299A2 (pt) Uso de composição, e, composição contendo proteína
BRPI1005670A8 (pt) composições adjuvantes e processos de uso.
BRPI0822221A2 (pt) Composições aquosas e estáveis de ciclosporina
BRPI1007494A2 (pt) composto e uso do mesmo
BRPI0812159A2 (pt) inibidores de csf-1r, composições e métodos de uso
BRPI0816995A2 (pt) Composições de ciclosporina
BRPI0817666A2 (pt) Composição com proteção uv
BRPI0808172A2 (pt) Compostos heterocíclicos, composições compreendendo-os e métodos de seu uso.
BRPI0907053A2 (pt) Poliisobutenoamina, composição combustível, e, uso de poliisobutenoaminas
BRPI0807920A2 (pt) Composições epilatórias

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.